Cambrex Adds Process Development Capabilities
Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility.
Cambrex Corporation announced plans for a $5-million expansion of laboratory facilities at its Karlskoga, Sweden site, which includes additional capability and capacity for process development and scale up, handling of potent substances, crystallization studies, and solid phase characterization. Construction on the three story, 600-sq.-m building will begin at the end of second quarter of 2018, with completion due in the second quarter of 2019, the company reported in a May 31, 2018 press announcement.
The expansion will feature a new technical laboratory with walk-in hoods for laboratory syntheses up to 10 L and will enable handling of potent substances at a large laboratory scale, high-pressure reactions, and parallel synthesis for API route scouting and development.
The expansion also will feature two analytical development and quality control laboratories and office space for 12 scientists and chemists, bringing the total headcount to 60.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
